Fortis Life Sciences Acquires Abcore

Fortis Life Sciences Acquires nanoComposix

July 23, 2021

Biotechnology

Fortis Life Sciences completed its acquisition of nanoComposix, a San Diego–based nanomaterials company focused on assay development, diagnostics and drug-delivery applications. The deal (closed June 2021) brings nanoComposix into the Fortis Life Sciences platform to expand its life-science reagents and contract-manufacturing capabilities and create synergies across the portfolio.

CoreRx Acquires Nucleo Life Sciences

May 24, 2021

Pharmaceuticals

CoreRx, Inc. has acquired Nucleo Life Sciences, a boutique CDMO based in San Rafael, California, expanding CoreRx’s US West Coast development presence and formulation capabilities. The deal, supported by CoreRx’s majority owner NovaQuest Private Equity and other shareholders, will integrate Nucleo’s Fast-to-Clinic formulation expertise (including spray-dried dispersions and NucleLoad) into CoreRx’s development and manufacturing platform.

Twist Bioscience Acquires Abveris

November 22, 2021

Biotechnology

Twist Bioscience entered into a definitive agreement to acquire Abveris (formerly AbX Biologics), an in vivo antibody discovery services company, for up to $190 million. The deal (approximately $150 million at closing in Twist common stock and up to $40 million contingent stock consideration plus limited cash) is intended to combine Abveris's mouse-based discovery platform with Twist's humanization and antibody engineering capabilities to broaden Twist's antibody discovery and biopharma services.

AbCellera Acquires TetraGenetics

September 13, 2021

Biotechnology

AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.

PerkinElmer Acquires Cisbio Bioassays from Abénex

April 26, 2019

Biotechnology

PerkinElmer has acquired Cisbio Bioassays from Abénex (with Cisbio management supporting the sale). Cisbio, headquartered in Codolet, France, is a manufacturer of HTRF assay kits, reagents and custom assay services with more than 200 employees; the acquisition expands PerkinElmer's life‑sciences reagent and screening technology portfolio.

Eurofins Discovery Acquires DiscoveryBioMed

July 5, 2022

Biotechnology

Eurofins Discovery has acquired DiscoveryBioMed, a Birmingham, Alabama–based contract research organization specializing in human primary- and immortalized-cell based bioassays. The acquisition strengthens Eurofins Discovery’s translational biology and human cell assay capabilities to expand its drug discovery services portfolio.